Adverse prognostic CT findings for patients with advanced lung adenocarcinoma receiving first-line epidermal growth factor receptor�tyrosine kinase inhibitor therapy

Suyon Chang, Jin Hur, Yoo Jin Hong, Hye Jeong Lee, Young Jin Kim, Kyunghwa Han, Byoung Wook Choi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

OBJECTIVE. The purpose of this study is to investigate adverse prognostic CT findings in patients with advanced-stage lung adenocarcinoma who are receiving epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) therapy as first-line therapy. MATERIALS AND METHODS. We included 199 patients (71 men and 128 women; mean ± SD age, 64.3 ± 11.2 years) with stage IIIB or IV lung adenocarcinoma who received first-line EGFR-TKI therapy between January 2009 and December 2015. Clinical findings and imaging parameters on CT images obtained before TKI therapy were analyzed, including tumor size, TNM category according to the seventh edition of the American Joint Committee on Cancer lung cancer TNM staging system, tumor type, the presence of cavity or necrosis, pleural effusion, and metastasis to pleura, lung, and distant organs. Response evaluation was performed according to the Response Evaluation Criteria in Solid Tumor version 1.1 guidelines. Correlation of clinical and radiologic findings with durations of progression-free survival (PFS) and overall survival (OS) was evaluated using a Cox proportional hazard model. RESULTS. Pleural effusion (hazard ratio [HR], 2.095; 95% CI, 1.394–3.147; p < 0.001) and an N2 or N3 tumor category (HR, 2.145; 95% CI, 1.280–3.594; p = 0.004) were significantly associated with a short PFS duration in multivariate analysis. Older age (HR, 1.040; 95% CI, 1.014–1.067; p = 0.002), an N2 or N3 tumor category (HR, 2.427; 95% CI, 1.068–5.518; p = 0.034), pleural effusion (HR, 1.903; 95% CI, 1.105–3.276; p = 0.020), and distant metastasis (HR, 2.795; 95% CI, 1.356–5.765; p = 0.005) were associated with a short OS duration in multivariate analysis. CONCLUSION. Pre–TKI therapy CT findings of pleural effusion and high N-category tumors are associated with short durations of PFS and OS in patients with lung adenocarcinoma who are receiving EGFR-TKI therapy.

Original languageEnglish
Pages (from-to)43-51
Number of pages9
JournalAmerican Journal of Roentgenology
Volume210
Issue number1
DOIs
Publication statusPublished - 2018 Jan

Fingerprint

Epidermal Growth Factor
Phosphotransferases
Pleural Effusion
Protein-Tyrosine Kinases
Epidermal Growth Factor Receptor
Disease-Free Survival
Neoplasm Staging
Neoplasms
Survival
Lung Neoplasms
Therapeutics
Multivariate Analysis
Neoplasm Metastasis
Pleura
Proportional Hazards Models
Adenocarcinoma of lung
Necrosis
Guidelines
Lung

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

@article{c08cb5f0451549fc80040171147fad19,
title = "Adverse prognostic CT findings for patients with advanced lung adenocarcinoma receiving first-line epidermal growth factor receptor�tyrosine kinase inhibitor therapy",
abstract = "OBJECTIVE. The purpose of this study is to investigate adverse prognostic CT findings in patients with advanced-stage lung adenocarcinoma who are receiving epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) therapy as first-line therapy. MATERIALS AND METHODS. We included 199 patients (71 men and 128 women; mean ± SD age, 64.3 ± 11.2 years) with stage IIIB or IV lung adenocarcinoma who received first-line EGFR-TKI therapy between January 2009 and December 2015. Clinical findings and imaging parameters on CT images obtained before TKI therapy were analyzed, including tumor size, TNM category according to the seventh edition of the American Joint Committee on Cancer lung cancer TNM staging system, tumor type, the presence of cavity or necrosis, pleural effusion, and metastasis to pleura, lung, and distant organs. Response evaluation was performed according to the Response Evaluation Criteria in Solid Tumor version 1.1 guidelines. Correlation of clinical and radiologic findings with durations of progression-free survival (PFS) and overall survival (OS) was evaluated using a Cox proportional hazard model. RESULTS. Pleural effusion (hazard ratio [HR], 2.095; 95{\%} CI, 1.394–3.147; p < 0.001) and an N2 or N3 tumor category (HR, 2.145; 95{\%} CI, 1.280–3.594; p = 0.004) were significantly associated with a short PFS duration in multivariate analysis. Older age (HR, 1.040; 95{\%} CI, 1.014–1.067; p = 0.002), an N2 or N3 tumor category (HR, 2.427; 95{\%} CI, 1.068–5.518; p = 0.034), pleural effusion (HR, 1.903; 95{\%} CI, 1.105–3.276; p = 0.020), and distant metastasis (HR, 2.795; 95{\%} CI, 1.356–5.765; p = 0.005) were associated with a short OS duration in multivariate analysis. CONCLUSION. Pre–TKI therapy CT findings of pleural effusion and high N-category tumors are associated with short durations of PFS and OS in patients with lung adenocarcinoma who are receiving EGFR-TKI therapy.",
author = "Suyon Chang and Jin Hur and Hong, {Yoo Jin} and Lee, {Hye Jeong} and Kim, {Young Jin} and Kyunghwa Han and Choi, {Byoung Wook}",
year = "2018",
month = "1",
doi = "10.2214/AJR.17.18167",
language = "English",
volume = "210",
pages = "43--51",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "1",

}

Adverse prognostic CT findings for patients with advanced lung adenocarcinoma receiving first-line epidermal growth factor receptor�tyrosine kinase inhibitor therapy. / Chang, Suyon; Hur, Jin; Hong, Yoo Jin; Lee, Hye Jeong; Kim, Young Jin; Han, Kyunghwa; Choi, Byoung Wook.

In: American Journal of Roentgenology, Vol. 210, No. 1, 01.2018, p. 43-51.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adverse prognostic CT findings for patients with advanced lung adenocarcinoma receiving first-line epidermal growth factor receptor�tyrosine kinase inhibitor therapy

AU - Chang, Suyon

AU - Hur, Jin

AU - Hong, Yoo Jin

AU - Lee, Hye Jeong

AU - Kim, Young Jin

AU - Han, Kyunghwa

AU - Choi, Byoung Wook

PY - 2018/1

Y1 - 2018/1

N2 - OBJECTIVE. The purpose of this study is to investigate adverse prognostic CT findings in patients with advanced-stage lung adenocarcinoma who are receiving epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) therapy as first-line therapy. MATERIALS AND METHODS. We included 199 patients (71 men and 128 women; mean ± SD age, 64.3 ± 11.2 years) with stage IIIB or IV lung adenocarcinoma who received first-line EGFR-TKI therapy between January 2009 and December 2015. Clinical findings and imaging parameters on CT images obtained before TKI therapy were analyzed, including tumor size, TNM category according to the seventh edition of the American Joint Committee on Cancer lung cancer TNM staging system, tumor type, the presence of cavity or necrosis, pleural effusion, and metastasis to pleura, lung, and distant organs. Response evaluation was performed according to the Response Evaluation Criteria in Solid Tumor version 1.1 guidelines. Correlation of clinical and radiologic findings with durations of progression-free survival (PFS) and overall survival (OS) was evaluated using a Cox proportional hazard model. RESULTS. Pleural effusion (hazard ratio [HR], 2.095; 95% CI, 1.394–3.147; p < 0.001) and an N2 or N3 tumor category (HR, 2.145; 95% CI, 1.280–3.594; p = 0.004) were significantly associated with a short PFS duration in multivariate analysis. Older age (HR, 1.040; 95% CI, 1.014–1.067; p = 0.002), an N2 or N3 tumor category (HR, 2.427; 95% CI, 1.068–5.518; p = 0.034), pleural effusion (HR, 1.903; 95% CI, 1.105–3.276; p = 0.020), and distant metastasis (HR, 2.795; 95% CI, 1.356–5.765; p = 0.005) were associated with a short OS duration in multivariate analysis. CONCLUSION. Pre–TKI therapy CT findings of pleural effusion and high N-category tumors are associated with short durations of PFS and OS in patients with lung adenocarcinoma who are receiving EGFR-TKI therapy.

AB - OBJECTIVE. The purpose of this study is to investigate adverse prognostic CT findings in patients with advanced-stage lung adenocarcinoma who are receiving epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) therapy as first-line therapy. MATERIALS AND METHODS. We included 199 patients (71 men and 128 women; mean ± SD age, 64.3 ± 11.2 years) with stage IIIB or IV lung adenocarcinoma who received first-line EGFR-TKI therapy between January 2009 and December 2015. Clinical findings and imaging parameters on CT images obtained before TKI therapy were analyzed, including tumor size, TNM category according to the seventh edition of the American Joint Committee on Cancer lung cancer TNM staging system, tumor type, the presence of cavity or necrosis, pleural effusion, and metastasis to pleura, lung, and distant organs. Response evaluation was performed according to the Response Evaluation Criteria in Solid Tumor version 1.1 guidelines. Correlation of clinical and radiologic findings with durations of progression-free survival (PFS) and overall survival (OS) was evaluated using a Cox proportional hazard model. RESULTS. Pleural effusion (hazard ratio [HR], 2.095; 95% CI, 1.394–3.147; p < 0.001) and an N2 or N3 tumor category (HR, 2.145; 95% CI, 1.280–3.594; p = 0.004) were significantly associated with a short PFS duration in multivariate analysis. Older age (HR, 1.040; 95% CI, 1.014–1.067; p = 0.002), an N2 or N3 tumor category (HR, 2.427; 95% CI, 1.068–5.518; p = 0.034), pleural effusion (HR, 1.903; 95% CI, 1.105–3.276; p = 0.020), and distant metastasis (HR, 2.795; 95% CI, 1.356–5.765; p = 0.005) were associated with a short OS duration in multivariate analysis. CONCLUSION. Pre–TKI therapy CT findings of pleural effusion and high N-category tumors are associated with short durations of PFS and OS in patients with lung adenocarcinoma who are receiving EGFR-TKI therapy.

UR - http://www.scopus.com/inward/record.url?scp=85039171781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039171781&partnerID=8YFLogxK

U2 - 10.2214/AJR.17.18167

DO - 10.2214/AJR.17.18167

M3 - Article

C2 - 29091002

AN - SCOPUS:85039171781

VL - 210

SP - 43

EP - 51

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 1

ER -